---
title: "300558.SZ (300558.SZ) — Related News"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/300558.SZ/news.md"
symbol: "300558.SZ"
name: "300558.SZ"
parent: "https://longbridge.com/en/quote/300558.SZ.md"
datetime: "2026-05-20T14:48:37.245Z"
locales:
  - [en](https://longbridge.com/en/quote/300558.SZ/news.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/300558.SZ/news.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/300558.SZ/news.md)
---

# 300558.SZ (300558.SZ) — Related News

### [Shimai Pharmaceutical rushes to the Hong Kong stock market: annual loss of 80.96 million, Betta Pharmaceuticals and Saizhi Bole are shareholders](https://longbridge.com/en/news/286747285.md)
*2026-05-18T09:35:22.000Z*
> Shimai Pharmaceuticals updates its prospectus and plans to list on the Hong Kong Stock Exchange. The company was establi

### [BETTA PHARMACEUTICALS: Application for Clinical Trial of Postoperative Adjuvant Treatment Indication for Icotinib Tablets IA2 High Risk-IB Accepted](https://longbridge.com/en/news/286239222.md)
*2026-05-13T10:12:40.000Z*
> BETTA PHARMACEUTICALS announced that its clinical trial application for the indication of postoperative adjuvant therapy

### [BETTA PHARMACEUTICALS: Currently, the commercialization promotion of Aofumin is still in the early stages](https://longbridge.com/en/news/286190151.md)
*2026-05-13T03:24:49.000Z*
> On May 12th, BETTA PHARMACEUTICALS stated at the performance briefing that the world's first recombinant human albumin i

### [The undervalued pharmaceutical company that is as stable as a dog has reversed this time](https://longbridge.com/en/news/284569905.md)
*2026-04-29T12:05:31.000Z*
> BETTA PHARMACEUTICALS recently announced its 2025 annual report and 2026 first-quarter report, showing significant chang

### [BETTA PHARMACEUTICALS Secretary of the Board Wu Lingxi resigns, a graduate with a master's degree in finance from Peking University, with an annual salary of 937,600 last year](https://longbridge.com/en/news/284142765.md)
*2026-04-27T02:43:18.000Z*
> The Secretary of the Board of Directors of BETTA PHARMACEUTICALS, Wu Lingxi, has resigned for personal reasons and will 

### [The first quarter report is impressive but faces senior management changes, BETTA PHARMACEUTICALS announces the resignation of its Secretary of the Board, and the company's R&D investment has been reduced for consecutive years](https://longbridge.com/en/news/284140421.md)
*2026-04-27T02:08:09.000Z*
> After releasing its first-quarter report, BETTA PHARMACEUTICALS experienced a change in senior management, as Secretary 

### [China National Radio Network looks at Zhejiang merchants | Ding Lieming: Twenty years of dreaming on the road of pharmaceutical innovation](https://longbridge.com/en/news/283667250.md)
*2026-04-22T12:19:12.000Z*
> China National Radio Zhejiang Channel launched a series of reports titled "China National Radio Looks at Zhejiang Mercha

### [BETTA PHARMACEUTICALS: Net profit in the first quarter was 236 million yuan, a year-on-year increase of 135.71%](https://longbridge.com/en/news/283662855.md)
*2026-04-22T12:09:59.000Z*
> BETTA PHARMACEUTICALS announced that in the first quarter of 2026, operating revenue was 1.04 billion yuan, a year-on-ye

### [BETTA PHARMACEUTICALS' subsidiary Xcovery has reached a commercialization cooperation agreement for ensartinib with the American company Eversana](https://longbridge.com/en/news/283110876.md)
*2026-04-17T08:16:44.000Z*
> Recently, BETTA PHARMACEUTICALS' subsidiary Xcovery Holdings, Inc. has reached a cooperation agreement with global comme